156 related articles for article (PubMed ID: 12449732)
1. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Kempin S; Gutierrez J; Wilson E; Lowery C; Diasio R
Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732
[TBL] [Abstract][Full Text] [Related]
2. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Köhne CH; Thuss-Patience P; Friedrich M; Daniel PT; Kretzschmar A; Benter T; Bauer B; Dietz R; Dörken B
Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
[TBL] [Abstract][Full Text] [Related]
3. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
4. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
5. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
6. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
7. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
[No Abstract] [Full Text] [Related]
8. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
9. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
Cunningham D
Tumori; 1997; 83(1 Suppl):S70-1. PubMed ID: 9154074
[No Abstract] [Full Text] [Related]
11. The potential role of Tomudex in the treatment of advanced colorectal cancer.
Sobrero AF
Tumori; 1997; 83(2):576-80. PubMed ID: 9226024
[TBL] [Abstract][Full Text] [Related]
12. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
13. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
Tsavaris N; Kosmas C; Vadiaka M; Kontos A; Fotia M; Angelopoulou A; Vrizidis N; Soulla M; Sougioultzis S; Koufos Ch
Invest New Drugs; 2002 Feb; 20(1):133-6. PubMed ID: 12003191
[TBL] [Abstract][Full Text] [Related]
14. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol NJ; Kennealey G; Seymour L
Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase inhibition, a dead end?
Herrmann R
Eur J Cancer; 1995 Nov; 31A(12):1919-20. PubMed ID: 8562141
[No Abstract] [Full Text] [Related]
16. Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Osterlund P; Orpana A; Elomaa I; Repo H; Joensuu H
Br J Cancer; 2002 Sep; 87(6):591-9. PubMed ID: 12237767
[TBL] [Abstract][Full Text] [Related]
17. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
[TBL] [Abstract][Full Text] [Related]
18. [Raltitrexed in colorectal cancer].
Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
[No Abstract] [Full Text] [Related]
19. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Wilson KS; Fitzgerald CA; Barnett JB; Gill S; Khoo KE
Cancer Invest; 2007 Dec; 25(8):711-4. PubMed ID: 18058467
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
Kerr DJ
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]